Sialic acid is used as a diagnostic and prognostic marker for leukemia. CD BioGlyco has developed a set of Strategies for Sialic Acid Analysis including Sialic Acid Analysis by LC-MS, Sialic Acid-Specific Bio-Affinity Strategies, and more. We provide sialic acid analysis services in leukemia samples according to each specific need of clients using these methods.
Leukemia is a blood cancer characterized by the abnormal proliferation of myeloid or lymphoid progenitor cells in the bone marrow, leading to impairment of normal hematopoiesis. According to data released by the International Agency for Research on Cancer (IARC), about 475,000 new cases of leukemia and 312,000 new leukemia deaths were reported worldwide in 2020. Leukemias are divided into acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL) depending on the type of abnormal cells and the maturity of the cells. Compared with other leukemias, AML has the highest incidence and highest mortality rate among hematological diseases, with a five-year survival rate of only 20%~30%.
Sialic acids are a family of 9-carbon carboxylated monosaccharides found at the outermost ends of N-linked and O-linked glycans and in lipid-associated glycoconjugates. In humans, the most common sialic acid is N-acetylneuraminic acid (Neu5Ac). Due to their unique structure, distribution location, and distribution ubiquity, sialic acids mediate a variety of physiological and pathological processes, such as cell recognition, cell adhesion, and protein targeting. Studies have shown that abnormal sialylation is closely related to the occurrence and development of tumors. Serum/plasma total sialic acid content, sialidase activity, sialyltransferase expression, and sialylation changes on specific serum glycoproteins may be used for clinical detection, staging, and treatment monitoring of cancer.
Fig.1 Structural features of the sialic acid family. (Pearce, 2016)
O-acetylation of sialic acid side chains at positions C-7, C-8, and C-9 is frequently found on glycoproteins or glycolipids of all higher vertebrates. Among them, O-acetylation at the C-9 position forms 9-O-acetylated sialic acid, which is the most common biological modification. Increased expression of 9-O-acetylated sialoglycoprotein and 9-O-acetylated disialoganglioside has been reported in lymphoblastoid cells of childhood ALL. It is used as a diagnostic and prognostic marker for childhood ALL. 9-O-acetylated sialic acid-specific IgM and IgG antibodies have been reported in ALL patients and have important implications in the detection and monitoring of patients.
CD BioGlyco has been focused on sialic acid research for many years and has developed systematic Strategies for Sialic Acid Analysis. Our analysis service has been recognized by researchers from many countries. If you are interested in our sialic acid analysis services in leukemia, please feel free to contact us.
Reference:
